As I read slide 22 of their presentation at the Rodman & Renshaw conference a few weeks ago, which is on the website under Investors/Webcasts & Presentations, they expect to present those results in early 2013. The website also has an updated poster presentation on that trial that was apparently presented on September 28 at the European Society for Medical Oncology conference. The results on disease progression and PSA decline seem generally consistent with what was presented earlier.
As stated in the "conclusions" section of the poster, they are starting a P2 trial of 427 with abiraterone. It's listed on clinicaltrials.gov as NCT01681433 but it's not yet recruiting. It's designed "to evaluate the anti-tumor effects of adding OGX-427 to continuing abiraterone acetate and prednisone treatment in men with metastatic castrate-resistant prostate cancer (MCRPC) who have prostate-specific antigen (PSA) progression" and will enroll 74 patients.